Based on the combined results of INTERACT-2 and ATACH-2, for spontaneous ICH patients presenting with an SBP of 150-220 mmHg, a target systolic blood pressure of 140 mm Hg is safe and can be effective for improving functional outcome.
Based on the PATCH trial, platelet transfusion is not recommended in patients taking antiplatelet therapy prior to onset of spontaneous ICH.
In patients with VKA (Vitamin K Antagonist) associated spontaneous ICH, BP reduction and INR reversal therapy should be initiated promptly and before transfer to tertiary care centers.
In patients with VKA associated spontaneous ICH, the findings of the INCH trial suggest that PCC is better than FFP in normalizing the INR within 3 hours and reducing hematoma expansion at 3 and 24 hours, although those effects on overall clinical outcomes remain unclear.
Disclaimer: All material and images included on this website are the sole property of CMC EM Residency and cannot be used or reproduced without written permission. Information contained on this website is the opinion of the authors and does not necessarily represent the official opinion of Carolinas HealthCare System or Carolinas Emergency Medicine Residency.
For Health Care Providers: Every effort is made to provide the most up to date evidence based medicine. However, this content may not necessarily reflect the standard of care and application of material contained on this website is at the discretion of the practitioner to verify for accuracy.
For the Public: This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Relying on information contained on this website is done at your own risk. Do not disregard professional medical advice or delay seeking care secondary to content on this website. Call 911 or seek a medical professional immediately for any medical emergencies.